Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer)
Sponsored by Jaeb Center for Health Research, in collaboration with University of Minnesota, Medtronic, Tandem Diabetes Care and Dexcom
Focus Areas: Beta Cell Therapies, Glucose Control Therapies
What is This Study?
In this Phase 3 trial, the effects of Hybrid Closed Loop (HCL) therapy, in conjunction with Verapamil will be tested on children aged 7-17 who have recently been diagnosed with diabetes.
There will be four different groups
- One group receiving HCL and verapamil
- One group receiving HCL and placebo
- One group receiving verapamil and not using HCL
- One group receiving placebo and not using HCL
Why do We Care?
Verapamil is a blood pressure medication that has been shown to slow the progression of type 1 diabetes. Hybrid Closed Loop therapy has been shown to improve nearly all outcomes over multiple daily injections (MDI) or traditional pump therapy. This trial is testing beta cell preservation as well as Glucose Control Therapy. It is truly a massive trial, which will likely improve the lives of many of it’s participants in concrete ways, and further the path to a cure for type 1 diabetes (T1D)!
When Might we See Results?
According to ClinicalTrials.gov, this trial has not yet begun recruiting, but was expected to start soon in April 2020. The estimated study completion date is March 2022.
Stay tuned for in-depth coverage from Beyond Type 1 on the results of this study. To learn more about this trial, click here